Abstract:Using bacteria for tumor-targeted therapy has attracted much attention in recent years. However, how to improve the targeted delivery and cancer therapy efficacy is an important but challenging scientific issue. Herein, a drug delivery system using a probiotic as a carrier was developed for tumor-targeted photodynamic and sonodynamic synergistic therapy. In this system, chlorin e6 (Ce6) nanoparticles (NPs) were prepared and incorporated into B. bifidum, followed by the conjugation of anti-death receptor 5 antibody (anti-DR5 Ab). Interestingly, B. bifidum under 671 nm laser or ultrasound (US) irradiation could generate reactive oxygen species (ROS), and Ce6–B. bifidum–anti-DR5 Ab obtained could target hypoxic regions in tumor with high efficiency after intravenous injection. The ROS level generated by Ce6–B. bifidum–anti-DR5 Ab under both laser and US irradiation was much higher than the combined ROS generated separately using a laser and US for the same probiotics. The cytotoxicity and laryngeal tumor growth-inhibiting efficiency of Ce6–B. bifidum–anti-DR5 Ab under both laser and US irradiation were significant higher than the values obtained using laser or US irradiation alone, which demonstrated the synergistic effect on tumor growth. B. bifidum could be eliminated from the body without exerting harmful effects on mouse health. This strategy is a platform that can be extended to treat other solid tumors.Statement of significanceUsing bacteria as drug delivery carriers will show unique advantages. However, how to improve the targeted delivery efficiency and tumor inhibiting capacity is a challenging scientific issue. Herein, a delivery system using a probiotic as carrier was developed for tumor-targeted therapy. In this delivery system, chlorin e6 nanoparticles were prepared and then incorporated into living Bifidobacterium bifidum (B.bifidum), followed by the conjugation of anti-death receptor 5 antibody. This delivery system could efficiently target to mouse tumors, accumulate the hypoxic areas and inhibit the tumor growth through the photodynamic and sonodynamic synergistic effect. Our results will provide a platform for B.bifidum–mediated tumor targeted therapy.

Bifidobacterium Longum As a Delivery System of TRAIL and Endostatin Cooperates with Chemotherapeutic Drugs to Inhibit Hypoxic Tumor Growth

Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Therapeutic Efficacy of Bifidobacterium Longum-Mediated Human Interleukin-2 with Endostatin or Trail in Transplanted Tumors in Mice

A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy

Bifidobacterium Longum As an Oral Delivery System of Endostatin for Gene Therapy on Solid Liver Cancer

Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29.

Selenium-Bifidobacterium Longum As A Delivery System of Endostatin for Inhibition of Pathogenic Bacteria and Selective Regression of Solid Tumor

Therapeutic Efficacy of Bifidobacterium Longum-Mediated Human Granulocyte Colony-Stimulating Factor And/Or Endostatin Combined with Cyclophosphamide in Mouse-Transplanted Tumors

Antitumor Efficacy of Bifidobacterium Longum Carrying Endostatin Gene Enriched with Selenium and the Distribution of Selenium

Tumor-targeted delivery of biologically active TRAIL protein

Bifidobacteria Expressing Tumstatin Protein for Antitumor Therapy in Tumor-Bearing Mice.

Bifidobacterium Adolescentis As a Delivery System of Endostatin for Cancer Gene Therapy: Selective Inhibitor of Angiogenesis and Hypoxic Tumor Growth

Target Colonization of Bifidobacterium Bifidum in Tumor-Bearing Mouse Model and Its Immune Activation on Macrophages.

Features of Bifidobacterium breve carrying ES and IFNγand its anti-tumor effect in mice with lung cancer

Improved Stability, Antitumor Effect, and Controlled Release of Recombinant Soluble TRAIL by Combining Genetic Engineering with Coaxial Electrospinning

Bifidobacterium breve as a delivery vector of IL-24 gene therapy for head and neck squamous cell carcinoma in vivo

Endostatin Gene Therapy Delivered by Attenuated Salmonellatyphimurium in Murine Tumor Models

Anti-tumor effect of sTRAIL eukaryotic expressing plasmid on human gastric cancer xenografts in nude mice

Nanodrug-loaded Bifidobacterium bifidum conjugated with anti-death receptor antibody for tumor-targeted photodynamic and sonodynamic synergistic therapy